drugset / Trial / NCT06826768
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
NaSingle-groupOpen-labelTreatment
Summary
A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab
Timeline
- Start
- 2025-07-09
- Primary completion
- 2027-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | Nezastomig | Monoclonal antibody | — | Intravenous |